For the first time in over 25 years (since the approval of oxybutynin in 1972), better medications are available for the overactive bladder. With the recent approval of tolterodine and oxybutynin ...

Medically reviewed by Mary Choy, PharmDMedically reviewed by Mary Choy, PharmD Overactive bladder ... muscles and increase ...

Botox is a prescription drug that’s used to treat certain bladder problems, such as overactive bladder (OAB) in adults. For certain bladder problems, Botox may also be prescribed to children ...

Prescription medications can ease overactive bladder symptoms. Supplements for overactive bladder may help, although little robust evidence supports their value. An overactive bladder (OAB ...

When this happens, symptoms associated with overactive bladder are reduced. Medications that fall under the beta-3 adrenergic ...

Gemtesa (vibegron) is a brand-name oral tablet prescribed for overactive bladder in adults. As with other drugs, Gemtesa can cause side effects. These include headache, urinary tract infection ...

Are you having problems with your bladder? There may be a more profound cause for the suffering than a random nuisance. The ...

Frequent urination often signals underlying health conditions that require medical attention. While occasional increases in ...

One in six adults have bladder control problems. It can disrupt sleep or cause accidents, lead to social isolation and depression and affects women more than men.

Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial.

There are many new treatment options for the overactive bladder that are discussed in this article, including the recently introduced drugs tolterodine and oxybutynin XL. Other drugs are in ...

Gemtesa (vibegron) is a prescription drug used to treat symptoms of overactive bladder (OAB). Gemtesa can cause side effects that range from mild to serious. Examples include headache, nausea ...